चिकित्सा अनुसंधान में प्रगति

चिकित्सा अनुसंधान में प्रगति
खुला एक्सेस

आईएसएसएन: 2564-8942


Prognostic value of Interleukin-8 in Colorectal Cancer

Jihene Ayari, Najet Mahjoub, Mehdi Balti, Rania Fehri, Abderrazek Haddaoui

Background Colorectal cancer is the third most common malignancy and 4th most common cause of cancer mortality worldwide. Pro-inflammatory cytokines may promote tumor malignant progression, invasion, and metastasis. The aim of this study was to measure serum levels of circulating IL8 and their correlation with conventional clinicpathologic prognostic indicators in colorectal cancer in Tunisia. Methods Serum samples were prospectively collected from a cohort of sixty colorectal cancer patients. Circulating levels of IL8 were measured with the technique of a solid-phase, two-site chemo-luminescent enzyme immune-metric assay (Immulite 1000, Simens, USA). Results The mean age of patients were 58 years (24 – 82 years), 36 men and 24 women with sex ratio:1.5. According to TNM stage we have found: 23.1% stage I and II, 35 % stage III and 41.7% stage IV, 25 patients were metastatic (60% in liver). Ras test was held on 20 Patients in which 13 were mutated one. Pre-treatment serum levels of CEA and carbohydrate antigen 19-9 were elevated on 26.6 % patients and 16.7% respectively. Among patients who had curative therapy (41 patients), only eleven relapsed with a median delay of 4.5 months. The mean level of IL8 was 61.9 þ/- 159.71pg/ml (min 5, max 1173pg/ml). We have found a significant correlation between high level of IL8 and advanced disease (p =0.001) especially with metastatic one (p =0.002) mutant RAS (p= 0.001), patients who had elevated pre-treatment CEA and CA19/9 levels and recurrent disease (0.032). Conclusion Our results highlight the role of IL8(CXCL8) in the serum as potential prognostic biomarkers in colorectal cancer patients which could contribute to tumor growth and progression. It could be a potential indicator for detecting colorectal cancer, predicting prognosis and an important target therapeutic in the future.